Vericel Corporation

Vericel Corporation

VCELNYSE / NASDAQHealthcareSmall cap

$57.52-$0.74 (-1.3%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
110.3x
EV / EBITDA
60.3x
Revenue
$276.3M
Net margin
6.0%
ROCE
5.1%

+52.0% over the last year

Vericel Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+41.7%
3M
+36.6%
6M
+62.5%
1Y
+52.0%
5Y
+29.8%

52-week range

Day change -$0.74 (-1.3%) from $58 to $58 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in VCEL, bought on each weekday since 2021.

News & filings

What Vericel filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthEBITDA grew 77.7% in fiscal 2025, 61.3 points more than revenue.

Concerns (1)

  • Return on equity of 4.7%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.

Read moreShow less

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
50.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
110.3x
P/B
5.1x
EV / EBITDA
60.3x
EV / Sales
6.4x
P/S
6.6x
52-week high
$59.45
52-week low
$29.34

Profitability

Operating margin
4.0%
Net margin
6.0%
EBITDA margin
10.7%
ROE
4.7%
ROCE
5.1%
ROA
3.4%
Asset turnover
0.57

Growth

Revenue
$276.3M
Revenue growth, 1Y
16.5%
Revenue CAGR, 3Y
18.9%
Net profit growth, 1Y
59.4%
Free cash flow
$24.7M

Solvency

Current ratio
5.03
Debt / Equity
0.27
Debt / Assets
0.20
CFO / Net profit
3.14
Cash / Market cap
7.5%

Where the revenue went

Of every $100 of FY2025 revenue, $6 was left as net income.

Vericel Corporation income statement flow, FY2025
Vericel Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$70.7M
RevenueGross profit$205.6M
Gross profitResearch and development$27.6M
Gross profitSelling, general and administrative$167.0M
Gross profitOther operating expenses$10.0k
Gross profitOperating income$11.0M
Operating incomePretax income$11.0M
Interest and other incomePretax income$6.3M
Pretax incomeTax and other$860.0k
Pretax incomeNet income$16.5M

Revenue and net profit

Revenue grew 16.5% in FY2025; net profit is the dashed line.

Vericel Corporation revenue and net profit by fiscal year
Vericel Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$164.4M-$16.7M
FY2023$197.5M-$3.2M
FY2024$237.2M$10.4M
FY2025$276.3M$16.5M

Cash flows

FY2025: $51.9M from operations, $24.7M free after investment (dashed).

Vericel Corporation operating and free cash flow by fiscal year
Vericel Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$17.7M$10.1M
FY2023$35.3M$7.8M
FY2024$58.2M-$5.8M
FY2025$51.9M$24.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$276.3M+16.5%1Y
EBITDA
$29.6M+77.7%1Y
Net profit
$16.5M+59.4%1Y
Cash from operations
$51.9M-10.8%1Y
Free cash flow
$24.7M
Revenue CAGR, 3Y
18.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$276.3M$29.6M$16.5M$24.7M4.7%+16.5%+59.4%

Monthly returns

Month-by-month returns of VCEL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$488.0M
Liabilities$133.3M
Equity$354.6M
Retained earnings-$376.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; VCEL highlighted.

P/E against peers

VCEL trades at 110.3x earnings against a peer median of -8.8x.

  1. Vericel Corporation (this company)110.3x

Not shown (no positive earnings and no EV / Sales): Rapport Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Vericel CorporationVCELthis company$1.8B110.3x5.1x4.7%60.3x
Zymeworks Inc.ZYME$1.8B-22.8x6.9x-30.2%-22.4x
Maravai LifeSciences Holdings, Inc.MRVI$1.8B-14.1x8.7x-61.6%-13.5x
Pediatrix Medical Group, Inc.MD$1.8B11.1x2.1x19.1%7.6x
Viridian Therapeutics, Inc.VRDN$1.8B-5.3x3.1x-58.1%-4.9x
ANI Pharmaceuticals, Inc.ANIP$1.8B23.0x3.3x14.5%10.3x
Nuvation Bio Inc.NUVB$1.8B-8.8x5.9x-66.9%-9.0x
Rapport Therapeutics, Inc.RAPP$1.8B—-178.2x-23.0%—
Surgery Partners, Inc.SGRY$1.8B-23.0x1.0x-4.5%9.9x
Peer median—-8.8x3.2x-26.6%-4.9x

Year-to-date ROI

VCEL since 1 January, against earlier years.

Historical volatility

VCEL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Vericel Corporation operating margin by fiscal year
Vericel Corporation operating margin by fiscal year
DateOperating margin
FY2022-10.4%
FY2023-3.3%
FY20241.9%
FY20254.0%
LineFY2025
Cost of revenueCost Of Revenue$70.7M
Gross profitGross Profit$205.6M
Operating expensesOperating Expense$194.6M
Research and developmentResearch And Development$27.6M
Selling, general and administrativeSelling General And Administration$167.0M
Total expensesTotal Expenses$265.2M
Pretax incomePretax Income$17.4M

Learn while you research

Academy chapters picked for Vericel Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 110.3, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →